CAMBRIDGE, Mass., Aug. 3, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced its participation in the following upcoming investor conferences:

• 37^th Annual Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 10, 2017 at 9:00 a.m. ET
• 2017 Wedbush PacGrow Healthcare Conference in New York, NY on Tuesday, August 15, 2017 at 10:20 a.m. ET

A live webcast of each presentation will be available by visiting the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following each presentation.

About Blueprint Medicines

Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other disease driven by the abnormal activation of kinases. Blueprint medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-august-300498939.html

SOURCE Blueprint Medicines Corporation

Kristin Hodous, 617-714-6674, khodous@blueprintmedicines.com; Jim Baker, 617-844-8236, jbaker@blueprintmedicines.com